FDA advisory panel votes that Galleri multi-cancer blood test benefits outweigh risks

On 23 September 2026 GRAIL, Inc. announced that the Molecular and Clinical Genetics Devices Panel of the FDA’s Medical Devices Advisory Committee voted in favor of its Premarket Approval (PMA) application for the Galleri multi-cancer early detection (MCED) blood test. In three votes among 10 voting members, the panel supported overall benefit–risk 7–2 with one abstention, voted unanimously that the test is safe, and voted 6–4 that it is effective for screening adults aged 50 years and older, according to the company release.

What Galleri is intended to do

Galleri is designed to detect shared cancer-specific methylation patterns in blood before symptoms appear, including cancers that lack routine screening today, and to predict a cancer signal origin to guide follow-up. GRAIL states it is meant to add to, not replace, guideline-recommended screening. The FDA designated Galleri a Breakthrough Device in 2018; GRAIL submitted the PMA on 29 January 2026.

The company says clinical development includes large interventional and randomised studies in intended-use populations, notably PATHFINDER 2 in North America and the NHS-Galleri trial in England (FDA-approved IDE studies). In those programmes GRAIL reports detecting roughly four to seven times more cancers than standard care alone, with many signals at earlier stages and a low false-positive rate — figures that come from the sponsor’s characterisation of its evidence package.

What the vote does — and does not — mean

FDA advisory committees give independent advice; the agency is not bound by the vote and will make a final PMA decision in coming months. Panel support for benefit–risk does not equal approval, reimbursement, or a change in screening guidelines. MCED tests raise open questions about overdiagnosis, confirmatory work-ups and outcomes that only longer follow-up can settle.

This article reports the panel vote and GRAIL’s stated evidence; it is not personal medical advice. Decisions about cancer screening belong with a clinician who knows a person’s history and local guidelines.